EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate cla

Dianthus reports 75% responder rate for claseprubart in CIDP, while analysts say Sanofi's rilipr

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.85) per share which beat the an

Wolfe Research analyst Andy Chen initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a

Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy

Wells Fargo analyst Sadia Rahman initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

Analysts change outlook on top names: Truist cut KFY price target, Oppenheimer raised AZO target, B.

Wall Street analysts upgraded CRWD, ALEC, RIVN, SEDG, and DNTH. See what other analysts say about th

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

Raymond James analyst Steven Seedhouse upgrades Dianthus Therapeutics (NASDAQ:DNTH) from Outperfo

Baird analyst Joel Beatty maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and rai

Clear Street analyst Bill Maughan maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and ra

Dianthus announced that it has commenced an underwritten public offering of $400 million of shares o

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DN

Oppenheimer analyst Leland Gershell maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperfo

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

Dianthus Therapeutics shares jump after early success in a Phase 3 trial for CIDP treatment clasepru

Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(1.43) per share which missed the

Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responder

Dow falls 100 pts, Latham Group Inc (SWIM) rises 25.7%, Babcock & Wilcox Enterprises Inc (BW) ga

Guggenheim analyst Yatin Suneja maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and rais

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

Jefferies analyst Maury Raycroft maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and rai

Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy

Wedbush analyst Laura Chico reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DN

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis,

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce

Truist Securities analyst Danielle Brill initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH

Clear Street analyst Bill Maughan initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with

Stifel analyst Alex Thompson maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ran

Raymond James analyst Steven Seedhouse reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Outp